Clinique’s Post

October is Eczema Awareness Month, and at Galderma, we recognize the challenges faced by those with eczema – from persistent dryness and itching to finding products that meet their needs. We also know that the need for impactful, at-home management is key in supporting this demographic. Our commitment to supporting patients and consumers drives the development of a handful of Cetaphil® innovations, several of which carry the National Eczema Association (NEA) Seal of Acceptance™. These products span multiple Cetaphil lines, providing a range of options to help people make informed choices for their skin health. The NEA Seal is given following a rigorous review process set by the NEA’s Scientific Oversight Committee, which consists of a panel of leading dermatologists, allergists and eczema experts. Submitted products go through a product evaluation to test for sensitivity, irritation and toxicity, as well as an ingredients and formulation data review. With 17 NEA-accepted products, including Cetaphil Sheer Mineral Sunscreen and Eczema Restoraderm® line, we are proud to support individuals at every step of their skin journey. At Galderma, advancing dermatology for every skin story means providing the impactful solutions to make a difference – not only during Eczema Awareness Month, but 365 days a year. #AdvancingDermatology #EczemaAwarenessMonth

Check out my article on JAK inhibitors in collaboration with DermOnDemand!

Topical Ivermectin and the Microbiome: New Insights into Rosacea Management Rosacea is a common chronic skin condition that causes facial redness, visible blood vessels, and often acne-like papules and pustules. It primarily affects adults over 30 and is often triggered by factors like heat, stress, spicy foods, alcohol, and an overgrowth of Demodex mites. The exact cause of rosacea remains unknown, but inflammation, immune dysfunction, and imbalances in the skin microbiome are key contributors. A recent study explored the effects of 1% topical ivermectin cream on rosacea and found it not only reduces Demodex density but also improves the skin microbiome balance. Study Highlights: • Participants: 10 adults with papulopustular rosacea (mean age: 66.4 years). • Duration: 12 weeks of daily ivermectin treatment. • Findings: • Significant reduction in Demodex density on affected skin (P = .002). • Increased abundance of Staphylococcus epidermidis on lesional skin (P = .039), potentially improving skin health. • Reduced papule counts and erythema scores (P = .002). • No changes in Cutibacterium acnes or on nonlesional skin. The study concluded that ivermectin improves rosacea symptoms by modulating the skin microbiome, providing relief beyond its known ability to reduce Demodex. Key Takeaway: “Treatment with topical ivermectin may improve the symptoms of rosacea through modulation of the skin microbiome beyond decreasing Demodex,” the authors stated, shedding light on new therapeutic opportunities. At Benehealth, we understand the challenges of rosacea and offer a range of treatments to address its symptoms and underlying causes. Whether through functional medicine, skincare consultations, or advanced therapies, our holistic approach aims to help you regain confidence and radiant skin. Published in: Journal of Investigative Dermatology Lead Author: Teruaki Nakatsuji, PhD, University of California, San Diego If you’re struggling with rosacea, explore how Benehealth’s tailored treatments can help you achieve healthier skin. Visit benehealth.com for more information. https://lnkd.in/eBfWRsVb

Our understanding of the therapeutic utility of CBD and other cannabinoids in dermatology is expanding rapidly! Recent research highlights its promising applications in various skin conditions. From ancient medical practices to modern clinical studies, CBD's benefits are gaining modern scientific recognition! Dermatological Potential: Atopic Dermatitis: CBD shows promise in managing the symptoms of atopic dermatitis, addressing inflammation, pruritus, and skin dryness. Research indicates its ability to regulate sebaceous glands (oil glands) and modulate immune responses within the skin. Psoriasis: CBD exhibits anti-inflammatory properties, potentially alleviating the symptoms of psoriasis by targeting abnormal keratinocyte proliferation and inflammation. Acne: CBD's anti-inflammatory and sebum-regulating properties offer a tool to combating acne, potentially addressing hormonal imbalances and microbial infections. Epidermolysis Bullosa: CBD may aid in managing skin fragility and blistering associated with this condition, offering relief from painful ulcerations. Systemic Sclerosis: CBD's anti-fibrotic and antioxidant properties hold promise in mitigating the pathological processes underlying systemic sclerosis, offering potential therapeutic avenues. Seborrheic Dermatitis & Scalp Psoriasis: CBD's anti-inflammatory and sebum-modulating effects could provide relief from the symptoms of these inflammatory dermatoses. Androgenetic Alopecia: CBD's potential in promoting hair growth and countering hair loss suggests a promising avenue for addressing androgenetic alopecia. (though the true utility remains disputed) Melanoma: Emerging evidence suggests CBD's potential in complementing conventional treatments for melanoma, offering hope in the fight against this aggressive skin cancer. The multivariant biological properties of CBD position it as a promising candidate for various skin-related conditions, making it exciting times ahead in dermatological cannabinoid research! #CBD #Dermatology Image credit (sorry for potato quality): Ferreira, B.P., Costa, G., Mascarenhas-Melo, F. et al. Skin applications of cannabidiol: sources, effects, delivery systems, marketed formulations and safety. Phytochem Rev 22, 781–828 (2023). https://lnkd.in/gcdyeXT3

In the recent Dermatology Times Expert Perspectives video series, “Exploring the Multifaceted Landscape of Atopic Dermatitis Care at the 2024 AAD Meeting,” 4 leading dermatologists explored key benchmarks, emerging trends, personalized medicine approaches, long-term safety considerations, and the integration of novel therapies in the management of #AtopicDermatitis. https://lnkd.in/gdmCmHbt

📰 FROM OUR PUBLICATION: Six #atopicdermatitis management and research leaders shared dozens of pearls to equip dermatology clinicians with the latest treatment advancements, guideline updates, and more, following #RAVE2024. https://lnkd.in/gvbHbsKe

Exciting news for the #Galderma team! After its approval earlier this year for prurigo nodularis, a rare skin disease, Galderma is taking another step forward in being able to offer potential relief to people in the U.S. with atopic dermatitis.  Galderma’s novel biologic NEMLUVIO has now received approval from the U.S. Food and Drug Administration for the treatment of patients 12 years of age and older for the treatment of moderate-to-severe atopic dermatitis. Another important milestone in Galderma’s growth journey. #Dermatology #Galderma #Nemluvio #AtopicDermatitis #AdvancingDermatology

#USAudience Today marks an important moment for the United States (U.S.) dermatology community and for U.S. patients suffering from atopic dermatitis (AD):  The U.S. Food and Drug Administration (FDA) has approved NEMLUVIO® (nemolizumab-ilto), 30 mg for injection for adults and pediatric patients 12 years and older with moderate to severe atopic dermatitis. Approximately 7% of people in the U.S. have atopic dermatitis – a common, chronic and flaring inflammatory skin disease, characterized by persistent itch and recurrent skin lesions. (1-4)   The approval brings a new treatment option for people living with AD in the U.S. and marks a major milestone in Galderma’s growth journey. Thank you to everyone who has been a part of this approval, including our talented teams and network of experts and healthcare professionals. Read more, including full Prescribing Information and Patient Information: https://lnkd.in/gFK3UZvB References: 1. Yang G, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8): 2867. doi: https://lnkd.in/gUVqPgvU 2. Langan SM, et al. Atopic dermatitis [published correction appears in Lancet. 2020;396(10253):758]. Lancet. 2020;396(10247):345-360. doi:10.1016/S0140- 6736(20)31286- 1 3. Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136-1143. doi:10.1056/NEJMra2023911 4. Silverberg JI, et al. Sleep Disturbances in Adults with Eczema Are Associated with Impaired Overall Health: A US Population-Based Study. J Invest Derm. 2015; 135, 56–66; doi:10.1038/jid.2014.325 - Important Safety Information  Indication: NEMLUVIO® (nemolizumab-ilto) is a prescription medicine used to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis or AD) in combination with prescription therapies used on the skin (topical) when the eczema is not well controlled by topical therapies alone. Contraindication: Known hypersensitivity to NEMLUVIO or any ingredients in NEMLUVIO. Warnings/Precautions: Hypersensitivity reactions have been reported with NEMLUVIO use. You should not receive a live vaccine right before or during treatment with NEMLUVIO. Adverse Events: Most common side effects of NEMLUVIO include: headache, joint pain, hives (itchy red rash or wheals) and muscle aches. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.  Please see full Prescribing Information including Patient Information at https://lnkd.in/g7ZJDcTf.

Dermatology research has long faced challenges due to datasets lacking diversity— often skewing toward lighter skin tones and lacking common conditions like rashes, infections and allergies. The Skin Condition Image Network (SCIN) addresses these critical gaps by providing a diverse and representative collection of over 10,000 skin condition images across various skin tones and body parts. This work, led by Stanford Medicine in collaboration with teams from Google Health and Google Research, has now been peer-reviewed and published in JAMA. Learn more about SCIN and its impact here: https://goo.gle/4fFukKY

📣 📊 🔬 NEW STUDY RESULTS: Data from the ADapt study presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference indicated #lebrikizumab improved skin clearance, reduced itch, and enhanced quality of life in patients with moderate-to-severe atopic dermatitis for whom dupilumab was not effective. Study co-author and Practical Dermatology editorial board member Raj Chovatiya, MD, PhD, MSCI, provides key insights on the results. Read more ➡️ https://lnkd.in/e9j888RM #skin #atopicdermatitis #lebrikizumab #skinhealth